Imunon, Inc. IMNN
0.63 USD -0.01 (-1.22%)
Regular-session close
0.60 -0.03 -4.96%
After hours · Nov 13, 4:29 PM ET
0.551 Day range 0.63
0.629 52-week range 4.22
- YTD
- -83.49%
- 1 year
- -84.88%
News
seekingalpha.com Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript
benzinga.com Imunon Q3 2026 Earnings Call Transcript Imunon (NASDAQ:IMNN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Imunon Q3 EPS $(0.64) Misses $(0.55) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 44.83 percent increase over losses of $(1.16)…
globenewswire.com IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
benzinga.com IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma TrialSale Reinforces IMUNON's…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions…
benzinga.com IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial 2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival resultsSupportive Preliminary MRD Study Data and translational findingsPathway to confirmatory readout…
benzinga.com IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to dateNo cytokine release syndrome, systemic…
benzinga.com IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001 Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimensIMUNON retains ownership of its background intellectual property…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma…
benzinga.com IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting…
benzinga.com Imunon Q2 EPS $(0.54) Beats $(0.93) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
benzinga.com EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study IMUNON posts rapid patient enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting completion by Q2 2029.
benzinga.com IMUNON To Present New Data On IMNN-001, DNA-Based Interleukin-12 Immunotherapy For Advanced Ovarian Cancer, At Inaugural AACR Conference On Drug Discovery And Development Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanismFirst-of-its-kind meeting spotlights…
benzinga.com Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMNN-001 in ovarian cancer.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
- benzinga.com Imunon Says Jeffrey Church To Retire As Interim CFO Effective July 1, 2026; Appoints Josh Blacher As Interim CFO Effective July 1, 2026 On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026),…
benzinga.com IMUNON Receives Independent Data Monitoring Committee Recommended Continuation Of Pivotal Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Neoadjuvant And Adjuvant Chemotherapy In Women With Newly Diagnosed Advanced Ovarian Cancer IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended…- benzinga.com IMUNON Enters Into Definitive Agreements For $10M In Preferred Stock And Secured Notes Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 millionUniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3…
- benzinga.com Imunon Reports Q1 2026 Results: Full Earnings Call Transcript
- benzinga.com Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com Maxim Group Initiates Coverage On Imunon with Buy Rating, Announces Price Target of $10 Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating and announces Price Target of $10.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(1.13) by 15.04 percent. This is a 56.67 percent increase over losses of $(3.00)…
- benzinga.com Earnings Scheduled For March 31, 2026
- benzinga.com Watching Imunon; Zacks Small-Cap Research Gives Stock $33 Price Valuation https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03252026_IMNN_Bautz.pdf
- benzinga.com IMUNON Reports Improved Survival In OVATION 2 Trial, With IMNN-001 Extending Overall Survival Up To 24.2 Months The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysisPatients…
- benzinga.com IMUNON Eliminates Headcount Not Essential To Phase 3 Trial Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 StudyKhursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Box Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session